H. Lundbeck (LUN) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Strategic reset and growth
Three-year reset focused on growing existing assets, building a long-term pipeline and disciplined capital allocation; the next phase is a scale phase.
Growth outlook extended to more than 2x the original 2023–2026 plan, based on October 2024 mid-term guidance and CER growth.
The ambition to build five to six mid- and late-stage assets was delivered; the pipeline shifted from lifecycle management and early-stage assets to a differentiated, more sustainable portfolio.
Commercial changes, partnership modifications, manufacturing optimization and fast deleveraging freed capital for growth and pipeline investment.
Commercial growth
Vyepti grew 45% CER and was described as the fastest-growing anti-CGRP in the U.S.; earlier-line use, Asia launches and European investment are growth opportunities, with IV administration not viewed as a limitation.
Rexulti grew 13% CER, with resilient momentum across indications; U.S. Alzheimer’s disease agitation was a key growth engine alongside MDD, and patients aged 65+ represent 37% of prescriptions.
MDD prescription growth was nearly 14% and AADAD growth was 29%; IRA pricing impact is expected in 2028, with further mid-term guidance planned for Q1 2027.
Vyepti and Rexulti have doubled the growth rate targeted three years ago, supporting a more durable growth engine.
Pipeline and catalysts
Bexicaserin DEEp OCEAN pivotal results are expected by end-2026 and DEEp SEA results in Q1 2027; broader DEE treatment could target peak sales of DKK 1.5bn–2bn, while another estimate is USD 1.5–2bn.
Amlenetug’s phase III multiple system atrophy study completed randomization; readout is expected in Q3 2027 from a 400-patient study building on phase II proof of concept.
Bocunebart phase III in chronic migraine was planned to start in 2026; anti-PACAP asedebart showed a 5.9-day LS mean reduction in monthly migraine days, while bocunebart showed cortisol normalization proof of concept in Cushing’s disease.
Phase Ib D1/D2 agonist Lu AF289964 showed 3.6 hours of good ON-time gained and 2.3 hours of OFF-time reduced at week 6 in advanced Parkinson’s disease; the pipeline also includes 16 special regulatory designations and a promising earlier-stage orexin program.
Latest events from H. Lundbeck
- Vyepti-led growth and stronger earnings lifted FY 2026 guidance as leverage fell.LUN
Q3 2026 - Vyepti-led growth lifted 9M results and FY 2026 guidance as leverage fell to 0.7x.LUN
Q3 2026 - Strategic-brand growth and pipeline investment support 2026 growth amid generic headwinds.LUN
Q4 2025 - Strong growth, innovation, and capital discipline drive long-term value and shareholder returns.LUN
Investor update - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - H1 2026 revenue up 16% CER, strong cash flow, and robust growth from Vyepti and Rexulti.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - Transformative year with late-stage pipeline advances and disciplined capital allocation.LUN
43rd Annual J.P. Morgan Healthcare Conference